Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opalia Pharma SA

Division of Recordati Industria Chimica & Farmaceutica SPA
www.opaliapharma.com.tn

Latest From Opalia Pharma SA

Biopharma Dealmaking Quarterly Statistics, Q3 2013

Biopharma financing in Q3 2013 totaled $4.6 billion, a 58% drop from the second quarter; Perrigo’s $8.3 billion acquisition of Elan made up more than half of the M&A dollar value; and marketed products made up the majority of licensed products.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, September 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Parent & Subsidiaries
  • Recordati Industria Chimica & Farmaceutica SPA
  • Senior Management
  • Alya El Hedda, Gen. Dir.
  • Contact Info
  • Opalia Pharma SA
    Phone: (216) 70 559 064
    Z.I Kalaat El Andalous
    Ariana, Tunisia, 2022
Advertisement
Advertisement
UsernamePublicRestriction

Register